Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation

Jacopo Romagnoli, Franco Citterio, Rosaria Calia, C Lai, P Aceto, M Luciani, S Lai, A Gargiulo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

This study investigated whether switching from the twice-daily (Prograf; TAC) to the once-daily formulation of tacrolimus with extended release (Advagraf; XL) affected quality of life, anxiety, and transplant benefit perception after allogeneic kidney transplantation.
Lingua originaleEnglish
pagine (da-a)1020-1023
Numero di pagine4
RivistaTransplantation Proceedings
Volume43
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Adult
  • Aged
  • Analysis of Variance
  • Anxiety
  • Delayed-Action Preparations
  • Drug Administration Schedule
  • Drug Monitoring
  • Female
  • Graft Rejection
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Immunosuppressive Agents
  • Italy
  • Kidney Transplantation
  • Male
  • Middle Aged
  • Perception
  • Psychiatric Status Rating Scales
  • Quality of Life
  • Questionnaires
  • Tacrolimus
  • Time Factors
  • Treatment Outcome
  • Truth Disclosure

Fingerprint

Entra nei temi di ricerca di 'Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation'. Insieme formano una fingerprint unica.

Cita questo